eligibility_summary
Include: prior MNPR-101-D001 participation, women of childbearing potential with negative pregnancy tests, all fertile use effective contraception during dosing and 3 months after, lactating women stop/avoid breastfeeding for 3 months. Exclude: recent chemo/radio/immunotherapy, unresolved ≥G3 AEs, recent radiopharmaceuticals (except MNPR-101-DFO-89Zr), organ dysfunction, significant MNPR-101-D001 safety events, unsafe dosimetry, serious comorbidity, inability to consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: MNPR-101-PCTA-177Lu, a radiolabeled monoclonal antibody (radioimmunotherapy). Drug type/mechanism: MNPR-101 targets urokinase plasminogen activator receptor (uPAR), the antibody is chelated with PCTA and loaded with lutetium-177, a beta-emitter. Binding to uPAR concentrates 177Lu at tumors, delivering localized ionizing radiation that induces DNA double-strand breaks and cell death, with a crossfire effect to nearby cells. Cells/pathways targeted: uPAR-expressing malignant cells and components of the tumor microenvironment (e.g., stromal cells such as cancer-associated fibroblasts and tumor-associated macrophages). Pathway focus: uPA/uPAR axis involved in ECM degradation, invasion/migration, and signaling via integrins/FAK/ERK.